Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS
Primary Purpose
Myelodysplastic Syndromes
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Peri-Transfusion QOL Assessment
Sponsored by
About this trial
This is an interventional health services research trial for Myelodysplastic Syndromes focused on measuring MDS, Myelodysplastic Syndromes, Quality of life, Tranfusion-dependent
Eligibility Criteria
Inclusion Criteria:
- Age > 18 years of age
- Patients with MDS
- Patients approaching an Hb of 8.5 g/dL during enrollment period OR
- Patients with >1 transfusion scheduled during an 8-week period
- Ability to read and understand English
Exclusion Criteria:
- Age <18 years
- Cr > 2
- Known CHF
- Unstable Angina
- Hb level below 7.5 g/dL or above 8.5 g/dL
- No plan for future transfusion.
- Patient enrollment will happen after patient has consented and scheduled their first/next transfusion.
- Patient will not be enrolled if no future transfusions are scheduled.
Sites / Locations
- Dana Farber Cancer Institute
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Peri-Transfusion QOL Assessment
Arm Description
Participants will be given a study packet containing a paper copy of the QUALMS Study participants will fill out the survey on the day before their first/next pRBC transfusion. Study participants will receive a second paper copy of the QUALMS, along with a stamped envelope addressed to the appropriate site The second assessment will be scored and compared with the first, and both the patient and provider will be sent a report with the results
Outcomes
Primary Outcome Measures
Rate of receipt of second transfusion (yes/no) (for those approaching first transfusion)
Assessed via medical record review at two months post index transfusion
Number of units pRBCs (for those transfusion-dependent)
Assessed via medical record review at two months post index transfusion
Number of hospitalizations (for both transfusion groups)
Assessed via medical record review at two months post index transfusion
Number of clinic visits (for both transfusion groups)
Assessed via medical record review at two months post index transfusion
Secondary Outcome Measures
PTQA Utilization
Assessed via follow-up survey at 2 months after index transfusion
Decisional regret
Assessed via follow-up survey at 2 months after index transfusion
Perceptions of care
Assessed via follow-up survey at 2 months after index transfusion
Perceived stress by the associated scales
Assessed via follow-up survey at 2 months after index transfusion
Full Information
NCT ID
NCT03660228
First Posted
September 4, 2018
Last Updated
January 6, 2022
Sponsor
Dana-Farber Cancer Institute
Collaborators
Vera and Joseph Dresner Foundation
1. Study Identification
Unique Protocol Identification Number
NCT03660228
Brief Title
Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS
Official Title
PTQA: A New Paradigm of Transfusion Decision Support for Patients With MDS
Study Type
Interventional
2. Study Status
Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
October 17, 2018 (Actual)
Primary Completion Date
June 30, 2021 (Actual)
Study Completion Date
June 30, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Dana-Farber Cancer Institute
Collaborators
Vera and Joseph Dresner Foundation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This research study is evaluating how to best tailor blood transfusion decisions to match the quality of life changes experienced by individual patients with MDS.
Detailed Description
Each patient with MDS reacts differently to blood transfusions; some will feel better after transfusion, while others may not. The main purpose of this survey study is to determine whether it is possible to use quality of life changes - as measured by a validated questionnaire - experienced by individual patients to help physicians and patients with MDS make decisions regarding future blood transfusions. This research is being done because the investigators hope to help doctors better understand the impact of blood transfusions on the quality of life of each patient.
The study uses a standardized MDS-specific quality of life questionnaire that participants will fill out before and after an upcoming transfusion. The investigators will compare the scores of these questionnaires and notify both the participant and provider if the participant has experienced any changes (positive or negative) in his/her quality of life before and after transfusion. The investigators' hope is that doctor-patient teams will use this quality of life information to determine whether the participant should continue receiving transfusions, decrease the frequency of transfusions, or stop receiving transfusions altogether if not needed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myelodysplastic Syndromes
Keywords
MDS, Myelodysplastic Syndromes, Quality of life, Tranfusion-dependent
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
62 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Peri-Transfusion QOL Assessment
Arm Type
Experimental
Arm Description
Participants will be given a study packet containing a paper copy of the QUALMS
Study participants will fill out the survey on the day before their first/next pRBC transfusion.
Study participants will receive a second paper copy of the QUALMS, along with a stamped envelope addressed to the appropriate site
The second assessment will be scored and compared with the first, and both the patient and provider will be sent a report with the results
Intervention Type
Other
Intervention Name(s)
Peri-Transfusion QOL Assessment
Intervention Description
Participants will undergo a peri-transfusion quality of life assessment (PTQA) using the Quality of Life in Myelodysplasia Scale (QUALMS)
Primary Outcome Measure Information:
Title
Rate of receipt of second transfusion (yes/no) (for those approaching first transfusion)
Description
Assessed via medical record review at two months post index transfusion
Time Frame
Two months
Title
Number of units pRBCs (for those transfusion-dependent)
Description
Assessed via medical record review at two months post index transfusion
Time Frame
Two months
Title
Number of hospitalizations (for both transfusion groups)
Description
Assessed via medical record review at two months post index transfusion
Time Frame
Two months
Title
Number of clinic visits (for both transfusion groups)
Description
Assessed via medical record review at two months post index transfusion
Time Frame
Two months
Secondary Outcome Measure Information:
Title
PTQA Utilization
Description
Assessed via follow-up survey at 2 months after index transfusion
Time Frame
Two months
Title
Decisional regret
Description
Assessed via follow-up survey at 2 months after index transfusion
Time Frame
Two months
Title
Perceptions of care
Description
Assessed via follow-up survey at 2 months after index transfusion
Time Frame
Two months
Title
Perceived stress by the associated scales
Description
Assessed via follow-up survey at 2 months after index transfusion
Time Frame
Two months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age > 18 years of age
Patients with MDS
Patients approaching an Hb of 8.5 g/dL during enrollment period OR
Patients with >1 transfusion scheduled during an 8-week period
Ability to read and understand English
Exclusion Criteria:
Age <18 years
Cr > 2
Known CHF
Unstable Angina
Hb level below 7.5 g/dL or above 8.5 g/dL
No plan for future transfusion.
Patient enrollment will happen after patient has consented and scheduled their first/next transfusion.
Patient will not be enrolled if no future transfusions are scheduled.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gregory A Abel, MD
Organizational Affiliation
Dana-Farber Cancer Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dana Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS
We'll reach out to this number within 24 hrs